Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis
Advances in Clinical and Experimental Medicine · 2023
DOI: 10.17219/acem/158488 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Advances in Clinical and Experimental Medicine, 2023. Verfasst von Shuheng Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Chongqing University Fuling Hospital, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Chongqing University Fuling Hospital, China.
- Department of Hepatobiliary and Pancreatic Surgery, Third Affiliated Hospital of Chongqing Medical University, China.
Zitieren
APA
Yang, S., Zhou, Y., & Zeng, L. (2023). Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/158488
Vancouver
Yang S, Zhou Y, Zeng L. Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Advances in Clinical and Experimental Medicine. 2023. doi:10.17219/acem/158488
BibTeX
@article{Yang2023,
author = {Yang, Shuheng and Zhou, Yadong and Zeng, Lei},
title = {Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis},
journal = {Advances in Clinical and Experimental Medicine},
year = {2023},
doi = {10.17219/acem/158488}
}
EUVIMED